N/A N=72 Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access
Heart Diseases
Primary: Transseptal Access Procedure Time — 2.3; 7.3 minutes — p=0.005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=109 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.
Down Syndrome · Amyloid Beta-protein
Primary: Sensitivity of the Independent Visual Assessment of Detecting Cerebral Amyloid-beta in Individuals With Down Syndrome and Specificity in Subjects Without Down Syndrome…
Phase 3 N=95 An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
Gaucher Disease, Type 1
Primary: Overall Summary of Treatment Emergent Adverse Events — 3; 1; 3; 38 Participants
Phase 2 N=288 Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
Hepatitis · Hepatitis C
Primary: Percentage of Participants With Sustained Viral Response (SVR) at Week 72 — 41.7; 39.6; 45.8 percentage of participants
N/A N=351 Comparing Surgery Versus Standard Physical Therapy in Treating People With a Meniscal Tear and Osteoarthritis
Osteoarthritis
Primary: WOMAC Functional Status - Difference From Baseline — 20.9; 18.5 Score — p=0.26
Phase 2 N=41 Erlotinib in Treating Patients With Advanced Kidney Cancer
Kidney Cancer
Primary: Number of Patients With Ani-tumor Activity After Taking OSI-774. — 7 participants
Phase 2 N=50 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Previously Treated Childhood Rhabdomyosarcoma · Recurrent Childhood Rhabdomyosarcoma · Recurrent Childhood Soft Tissue Sarcoma
Primary: Response (Complete Response [CR] and Partial Response [PR]) — 1; 0; 0; 0 participants
N/A N=2,765 A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)
Allergic Rhinoconjunctivitis
Primary: Percentage of Participants Who Experienced Daily Symptoms Due to Allergic Rhinoconjunctivitis (ARC) — 41; 39; 38; 29 percentage of participants
N/A N=13 Intranasal CO2 for Allergic Rhinitis
Allergic Rhinitis
Primary: Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge — 6; 19.6 milligrams
Phase 2 N=23 Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Recurrent Melanoma · Stage IIA Melanoma · Stage IIB Melanoma
Primary: Objective Response Rate — 0 percentage of participants
Phase 2 N=63 Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects
Human Influenza
Primary: Percentages of Subjects Who Achieved Seroconversion or Significant Increase in SRH Area Against Each of Three Vaccine Strains After One Vaccination of aTIV — 59; 65; 81…
Phase 2 N=46 A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy
Prostate Cancer
Primary: To Determine the Proportion of Patients With Metastatic CRPC Who do Not Have Prostate Specific Antigen (PSA) Progression After 24 Weeks of Therapy With One of Two…
Phase 1 N=12 An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers
Methamphetamine Addiction · Crystal Meth Addiction · Amphetamine Addiction
Primary: Systolic Blood Pressure — 126.4; 127.4 mm Hg
Phase 3 N=40 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Healthy
Primary: Gastric Volume — 262; 718 mL — p=<0.0001
N/A N=35 Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — -.70; 1.84 cm/sec — p=.4414